PresseKat - DGAP-News: Apricus Biosciences Announces Issuance of Key Patent for RayVa(TM) for Raynaud's Phe

DGAP-News: Apricus Biosciences Announces Issuance of Key Patent for RayVa(TM) for Raynaud's Phenomenon in Israel

ID: 416965

(firmenpresse) - Apricus Biosciences, Inc.

31.05.2011 15:55
---------------------------------------------------------------------------

Coverage Also Expands to Wound Healing, Inflammatory Skin Lesions and Certain
Skin Conditions

SAN DIEGO, 2011-05-31 15:55 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that the Israeli Patent Office has
allowed and granted the Company a patent entitled, 'Topical Compositions for
Prostaglandin E1 Delivery.' The patent, for the use of Prostaglandin E1
(otherwise known as 'PGE1' or 'alprostadil') in combination with the Company's
proprietary NexACT(r) technology for Raynaud's Phenomenon covering its drug
candidate RayVa?, among other potential product candidates, will provide
coverage to May 13, 2019 and expands the protection for Apricus Bio's
alprostadil-based products in Israel to eight granted patents.

The patent covers the combination of alprostadil and the Company's proprietary
NexACT(r) technology, which consists of a small permeation enhancer called
Dodecyl 2-(N,N dimethylamino)-propionate ('DDAIP') and enables the rapid
absorption of high concentrations of an active pharmaceutical ingredient at the
target site that is designed to enhance the delivery of an active drug to the
patient. Obtaining the patent represents an important achievement for the
Company in the protection of its late stage drug candidate, RayVa?, for the
treatment of Raynaud's Phenomenon. Apricus Bio expects to submit to the FDA an
adaptive Phase 3 protocol for Special Protocol Assessment for review before the
end of 2011 and the Company is currently evaluating in its pre-clinical
programs a number of other indications included in the patent, such as wound
healing, inflammatory skin lesions and other skin conditions.

The addition of this patent adds to the Company's worldwide portfolio of issued




patents for topical compositions targeted to theses types of skin diseases and
disorders in over 25 countries, including the United Stated, Canada and various
European nations, among others.

Commenting on today's news, Dr. Bassam B. Damaj, Ph.D., the Company's Chairman,
President and Chief Executive Officer stated, 'We are pleased with the further
expansion of our patent portfolio to cover the use of alprostadil and our
NexACT(r) technology for our late stage product RayVa? for Raynaud's Phenomenon
and other indications. We look forward to the development of RayVa? and other
topically-based products to help patients who suffer from such ailments.'

About Apricus Biosciences, Inc.

Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has
leveraged the flexibility of its clinically-validated NexACT(r) drug delivery
technology to enable multi-route administration of new and improved compounds
across numerous therapeutic classes.

Revenues and growth are driven from out-licensing of this technology for the
development and commercialization of such compounds to pharmaceutical and
biotechnology companies worldwide. In addition, the Company is seeking to
monetize its existing product pipeline, including its first product, Vitaros(r),
approved in Canada for the treatment of erectile dysfunction, which is
currently expected to be available on the Canadian market in 2011, as well as
compounds in development from pre-clinical through Phase III, currently focused
on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain,
Anti-Infectives, Diabetes and Cosmeceuticals among others.

For further information on Apricus Bio, visit http://www.apricusbio.com and for
information on its subsidiaries please visit www.nexmedusa.com or
www.bio-quant.com. You can also receive information at
http://twitter.com/apricusbio and http://facebook.com/apricusbio.

Apricus Bio's Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further development products and
product candidates such as RayVa?, and other products that use alprostadil and
the Company's NexACT(r) technology, to successfully commercialize such products
and product candidates and to achieve its other development, commercialization
and financial goals. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read the risk
factors set forth in the Company's most recent annual report on Form 10-K,
subsequent quarterly reports filed on Form 10-Q and other filings made with the
SEC. Copies of these reports are available from the SEC's website or without
charge from the Company.


Apricus Biosciences, Inc.
Edward Cox, V.P.
Investor Relations&Corporate Development, Apricus Bio, Inc.
(858) 848-4249
ecox(at)apricusbio.com

Apricus Bio Investor Relations
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz(at)rxir.com
News Source: NASDAQ OMX



31.05.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: Apricus Biosciences, Inc.


United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:

End of Announcement DGAP News-Service

---------------------------------------------------------------------------

Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  DGAP-News: Hauptversammlung beschließt Dividendenausschüttung von EUR 0,65 je Aktie DGAP-News: Orko Silver Corp.: Aktuelle Informationen des Präsidenten
Bereitgestellt von Benutzer: EquityStory
Datum: 31.05.2011 - 15:55 Uhr
Sprache: Deutsch
News-ID 416965
Anzahl Zeichen: 6995

Kontakt-Informationen:

Kategorie:

Wirtschaft (allg.)



Diese Pressemitteilung wurde bisher 0 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"DGAP-News: Apricus Biosciences Announces Issuance of Key Patent for RayVa(TM) for Raynaud's Phenomenon in Israel"
steht unter der journalistisch-redaktionellen Verantwortung von

Apricus Biosciences, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Apricus Biosciences, Inc.